ACADIA Pharmaceuticals Inc. · NASDAQ:ACAD
ACADIA Pharmaceuticals — Q3 2026 Earnings Presentation
25 slides from ACADIA Pharmaceuticals's earnings presentation, Nov 4, 2026
Slide 1: Third Quarter 2026 Earnings Call
Third Quarter 2026 Earnings Call November 4, 2026
Slide 2: Call Agenda
Call Agenda Welcome Financial Update Al Kildani Mark Schneyer Senior Vice President, IR and Corporate Communications Executive Vice President, Chief Financial Officer CEO Opening Remarks Closing Remarks Catherine Owen Adams Catherine Owen Adams Chief Executive Officer Chief Executive Officer Commerc
Slide 3: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements other than statements of historical fact and can be identified by terms such as “may,” “will,
Slide 4: Opening Remarks
Opening Remarks Catherine Owen Adams CHIEF EXECUTIVE OFFICER 4
Slide 5: Third Quarter Highlights
Third Quarter Highlights R&D Q3 sales $140M, Q3 sales $202M, Announced Phase 3 enabling +39% YoY driven primarily by +12%* YoY data for remlifanserin in ADP US STIX momentum Growth driven primarily by Data from ILLUMERA Phase 2 Granted new patent allowance volume study of remlifanserin in LBDP exten
Slide 6: Commercial Update
Commercial Update Tom Garner CHIEF COMMERCIAL OFFICER 6
Slide 7: DAYBUE Updates
DAYBUE Updates DAYBUE Net Sales 150 $140M +39% $140M +39% +13% Q3 Net Sales* YoY Growth 125 • Record, volume-driven growth with DAYBUE STIX $101M expanding the opportunity through new patient 100 starts and patient restarts • Launched commercially in Europe (Germany) 75 • New U.S. patent protection
Slide 8: DAYBUE Growth Drivers Support Long-Term Opportunity
DAYBUE Growth Drivers Support Long-Term Opportunity STIX Adoption Building European Expansion Momentum Continued new patient uptake and Received European Commission approval restarts provide two distinct opportunities to drive sustained growth Launched commercially in Germany with patients already r
Slide 9: NUPLAZID Updates
NUPLAZID Updates NUPLAZID Net Sales $202M Q3 Net Sales +12% YoY Growth* 200 $202M +12%* $180M* 175 • NBRx trends support continued volume-driven growth 150 • Sales force expansion increasing HCP engagement, with meaningful potential upside as productivity matures 125 • DTC investment expanding PDP a
Slide 10: R&D Update
R&D Update Sanjeev Pathak, M.D. SENIOR VICE PRESIDENT | HEAD OF CLINICAL DEVELOPMENT 10
Slide 11: Neurological and Rare Diseases Products and Pipeline
Neurological and Rare Diseases Products and Pipeline IND PROGRAM INDICATION MOLECULE DESCRIPTION DISCOVERY PHASE 1 PHASE 2 PHASE 3 LAUNCHED ENABLING Neurological diseases NUPLAZID® Parkinson's Disease Psychosis 5HT2A inverse agonist and antagonist Remlifanserin (ACP-204) Alzheimer's Disease Psychosi
Slide 12: RADIANT: Phase 2 Remlifanserin ADP Data Enable Phase 3
RADIANT: Phase 2 Remlifanserin ADP Data Achieve Goals of Enabling Phase 3 Dose Selection and Design Optimization Efficacy Safety & Tolerability Phase 3 Enabling Narrowly missed primary Favorable safety and tolerability Data support the continued endpoint (SAPS H+D) for profile development of remlifa
Slide 13: Remlifanserin Efficacy Across Psychosis Scales
Remlifanserin Efficacy Across Psychosis Scales Endpoint Dose N¹ Difference vs placebo (95% CI) at Week 6 p-value Effect Size SAPS H+D 60 mg 107/109 -2.2 (-4.5, 0.1) 0.0603 0.26 Total Score NPI/NPI-NH 60 mg 99/108 -1.5 (-2.8, -0.1) 0.0385 0.29 Psychosis Score -5 -4 -3 -2 -1 0 1 2 Favors remlifanserin
Slide 14: Phase 2 Study Safety Profile Supports Continued Phase 3 Development
Phase 2 Study Safety Profile Supports Continued Phase 3 Development • No signal of QT prolongation vs placebo • Low rates of serious adverse events and discontinuations due to adverse events • No AE was seen in more than 5% of patients receiving 60 mg remlifanserin • Only somnolence (3.2%) and nause
Slide 15: Key Changes to Ongoing Phase 3 RADIANT Program
Key Changes to Ongoing Phase 3 RADIANT Program Phase 3 program in ADP: enrollment continuing, with protocols updated based on Phase 2 learnings Dose Key changes intended to improve the ability to detect a treatment effect 60 mg Refined site selection Based on site performance in Phase 2 Focus of Pha
Slide 16: Two Phase 2 Readouts Expected in 2027
Two Phase 2 Readouts Expected in 2027 in Areas of Significant Unmet Need Remlifanserin Lewy body dementia psychosis Q4 2027 ACP-211 Major depressive disorder 2H 2027 ILLUMERA Phase 2 results NORLIGHT Phase 2 results • Novel, highly selective 5-HT2A inverse agonist, • Oral, deuterated R-norketamine m
Slide 17: Financial Update
Financial Update Mark Schneyer CHIEF FINANCIAL OFFICER 17
Slide 18: Q3 2026 Financial Highlights
Q3 2026 Financial Highlights Millions, Except EPS 3Q26 3Q25 YoY Change TOTAL Revenue $342.3 $280.9* 22%* DAYBUE $140.1 $101.1 39% NUPLAZID $202.2 $179.8* 12%* R&D $76.3 $87.8 (-13%) SG&A $159.2 $133.4 19% EPS (diluted) $0.31 $0.42 - Cash and Investments Balance $976.4 * Represents Non-GAAP adjusted
Slide 19: FY 2026 Financial Guidance
FY 2026 Financial Guidance Updated Guidance* Prior Guidance* NUPLAZID Net Sales $760 to $775 Million $760 to $790 Million NUPLAZID Gross-to-Net 22% to 23% 22% to 24% DAYBUE Net Sales1 $505 to $520 Million $480 to $510 Million DAYBUE Gross-to-Net 23% to 24% 23% to 25% Total Revenue $1.265 to $1.295 B
Slide 20: Concluding Remarks
Concluding Remarks Catherine Owen Adams CHIEF EXECUTIVE OFFICER 20
Slide 21: Acadia is Positioned for the Next Phase of Growth
Acadia is Positioned for the Next Phase of Growth PROVEN EXECUTION • Excellent third quarter for DAYBUE® and NUPLAZID® Commercial momentum across both brands • Continued momentum expected through year-end TRANSFORMATIONAL OPPORTUNITY • RADIANT in ADP: efficacy signal observed at 60 mg; insights to R
Slide 22: Q&A Session
Q&A Session OS ACADIA _
Slide 23: Appendix
Appendix OK ACADIA
Slide 24: Non-GAAP Reconciliation
Non-GAAP Reconciliation 3Q25 3Q26 GAAP NUPLAZID Net Product Sales $177.5 $202.2 Change in estimate recorded in period $4.9 — Allocation of 2025 Amount (2.6) — Non-GAAP Adjusted NUPLAZID Net Product Sales $179.8 $202.2 DAYBUE Net Product Sales $101.1 $140.1 Non-GAAP Adjusted Total Revenue $280.9 $342
Slide 25: Terms of Agreement with Neuren for DAYBUE/DAYBU in North America and Europe
Terms of Agreement with Neuren for DAYBUE/DAYBU (trofinetide) in North America and Europe North America Europe3 Tiered Royalty Rates (annual net sales)1 Tiered Royalty Rates (annual net sales)1 ≤$250M 10% ≤$150M 17% >$250M, but ≤$500M 12% >$150M, but ≤$300M 20% >$500M, but ≤$750M 14% >$300M 23% >$75
Acadia Pharmaceuticals — Q3 2026 Earnings Presentation on 6ix